

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
**WO 2004/052933 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 16/00**
- (21) International Application Number:  
PCT/GB2003/005436
- (22) International Filing Date:  
12 December 2003 (12.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0228939.5 12 December 2002 (12.12.2002) GB
- (71) Applicant (*for all designated States except US*): **THE UNIVERSITY OF NOTTINGHAM** [GB/GB]; Trent Building, University Park, Nottingham NG7 2RD (GB).
- (72) Inventors; and  
(75) Inventors/Applicants (*for US only*): **BONEHAM, Steven, Paul** [GB/GB]; School of Molecular Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH (GB). **BALL, Jonathan, Kelvin** [GB/GB]; School of Molecular Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH (GB).
- (74) Agent: **MILES, John**; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **PEPTIDE PRESENTATIONS FOR HUMAN IMMUNODEFICIENCY VIRUS VACCINES**

(57) Abstract: Partially occluded and/ or multimeric presentations of peptides mimic the epitopes recognised by antibodies capable of neutralising diverse clinical isolates of the human immunodeficiency virus type 1 (HIV-1). By "partially occluded" is meant a presentation that has a three-dimensional structure (probably a barrel/cylindrical/ helical shape) generated by inter-chain disulphide bridging or other means that has internally, at or near its base, the epitope that is recognised by the neutralising antibody; i.e. a partially occluded presentation is a three-dimensional presentation of one or more neutralising epitopes such that the epitope is located in a pocket or cleft. Such presentations are better at eliciting antibodies that have the neutralising phenotype, and may be used as vaccines or to produce antibodies for the prevention or treatment of HIV-1 infection.